BACKGROUND

Minimal access breast surgery (MABS) is commonly employed in the management of breast cancer, but there is limited research on the postoperative immune function associated with MABS.

OBJECTIVE

This study aimed to assess the postoperative immune function in breast patients who underwent MABS or conventional open breast surgery (COBS).

METHODS

We retrospectively analyzed the medical records of 829 breast cancer patients treated with either MABS or COBS at a single hospital between January 2020 and June 2023. Among them, 116 matched pairs were obtained through 1:1 propensity score matching (PSM). Flow cytometry was used to measure the percentages of CD3, CD4, and CD8 cells, as well as the CD4/CD8 ratio, on three different time points: preoperative day 1 (PreD1), postoperative day 1 (PostD1), and postoperative day 7 (PostD7).

RESULTS

Both the MABS and COBS groups demonstrated a significant reduction in the percentages of CD3, CD4, and CD8 cells, along with the CD4/CD8 ratio, from PreD1 to PostD1. Interestingly, the MABS group showed a reversal of these parameters, returning to preoperative levels by PostD7. Conversely, the COBS group showed an increase in these parameters from PostD1 to PostD7, but they still remained significantly lower than preoperative levels at PostD7.

CONCLUSION

MABS treatment may result in reduced postoperative immune suppression and faster recovery of preoperative immune function compared to COBS in patients.